MA35430B1 - Procédés de réduction du taux de lipoprotéine(a) par l'administration d'un inhibiteur de proprotéine convertase subtilisine/kexine-9 (pcsk9) - Google Patents
Procédés de réduction du taux de lipoprotéine(a) par l'administration d'un inhibiteur de proprotéine convertase subtilisine/kexine-9 (pcsk9)Info
- Publication number
- MA35430B1 MA35430B1 MA36809A MA36809A MA35430B1 MA 35430 B1 MA35430 B1 MA 35430B1 MA 36809 A MA36809 A MA 36809A MA 36809 A MA36809 A MA 36809A MA 35430 B1 MA35430 B1 MA 35430B1
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitor
- level
- methods
- lipoprotein
- administering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Abstract
La présente invention concerne des procédés permettant de réduire le taux de lipoprotéine(a) (lp(a)) chez un patient. Les procédés de la présente invention comprennent la sélection d'un patient présentant un taux sérique élevé de lp(a) et l'administration au patient d'une composition pharmaceutique contenant un inhibiteur de pcsk9. Dans certains modes de réalisation, l'inhibiteur de pcsk9 est un anticorps anti-pcsk9, tel que l'anticorps appelé mab316p dans le mémoire de l'invention.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161535392P | 2011-09-16 | 2011-09-16 | |
US201161559162P | 2011-11-14 | 2011-11-14 | |
US201261641321P | 2012-05-02 | 2012-05-02 | |
PCT/US2012/054756 WO2013039969A1 (fr) | 2011-09-16 | 2012-09-12 | Procédés de réduction du taux de lipoprotéine(a) par l'administration d'un inhibiteur de proprotéine convertase subtilisine/kexine-9 (pcsk9) |
Publications (1)
Publication Number | Publication Date |
---|---|
MA35430B1 true MA35430B1 (fr) | 2014-09-01 |
Family
ID=46881178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA36809A MA35430B1 (fr) | 2011-09-16 | 2014-03-06 | Procédés de réduction du taux de lipoprotéine(a) par l'administration d'un inhibiteur de proprotéine convertase subtilisine/kexine-9 (pcsk9) |
Country Status (21)
Country | Link |
---|---|
US (2) | US10076571B2 (fr) |
EP (3) | EP2756004B1 (fr) |
JP (2) | JP6158813B2 (fr) |
KR (1) | KR101964031B1 (fr) |
CN (2) | CN111789944A (fr) |
AR (1) | AR087881A1 (fr) |
AU (1) | AU2012308797B2 (fr) |
BR (1) | BR112014005522A2 (fr) |
CA (1) | CA2848201C (fr) |
CL (1) | CL2014000605A1 (fr) |
CO (1) | CO6910163A2 (fr) |
EA (1) | EA028278B1 (fr) |
ES (2) | ES2773111T3 (fr) |
IL (1) | IL231011B (fr) |
MA (1) | MA35430B1 (fr) |
MX (1) | MX363642B (fr) |
MY (1) | MY170089A (fr) |
SG (1) | SG2014010524A (fr) |
TW (1) | TWI601740B (fr) |
WO (1) | WO2013039969A1 (fr) |
ZA (1) | ZA201401114B (fr) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
PL3395836T3 (pl) | 2011-01-28 | 2021-12-13 | Sanofi Biotechnology | Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników |
AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
EP2756004B1 (fr) | 2011-09-16 | 2019-12-25 | Regeneron Pharmaceuticals, Inc. | INHIBITEUR DE PROPROTÉINE CONVERTASE SUBTILISINE/KEXINE-9 (PCSK9) POUR L'UTILISATION DANS LA RÉDUCTION DU TAUX DE LIPOPROTÉINE(a) |
US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
BR112015026513A2 (pt) | 2013-04-17 | 2017-07-25 | Pfizer | derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares |
TWI682780B (zh) * | 2013-05-30 | 2020-01-21 | 美商再生元醫藥公司 | 醫藥組成物用於製造治療與pcsk9功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途 |
US10111953B2 (en) * | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
TW202021614A (zh) | 2013-06-07 | 2020-06-16 | 法商賽諾菲生物技術公司 | 藉由投與pcsk9抑制劑抑制動脈粥狀硬化的方法 |
KR20230119045A (ko) * | 2013-10-11 | 2023-08-14 | 사노피 바이오테크놀로지 | 고지혈증을 치료하기 위한 pcsk9 억제제의 용도 |
EP3068803B1 (fr) | 2013-11-12 | 2021-01-20 | Sanofi Biotechnology | Schémas posologiques pour l'utlisation d' inhibiteurs de la pcsk9 |
US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US9045548B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment |
US9023359B1 (en) | 2014-07-15 | 2015-05-05 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US9034332B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
US9051378B1 (en) | 2014-07-15 | 2015-06-09 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
CN106062004A (zh) * | 2013-12-17 | 2016-10-26 | 科马布有限公司 | 人靶标 |
US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
EA201691320A1 (ru) * | 2014-02-14 | 2016-11-30 | Ридженерон Фармасьютикалз, Инк. | Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
ES2876409T3 (es) | 2014-04-25 | 2021-11-12 | Univ Pennsylvania | Variantes del RLBD y su uso en composiciones para reducir los niveles de colesterol |
US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
US9150660B1 (en) | 2014-07-15 | 2015-10-06 | Kymab Limited | Precision Medicine by targeting human NAV1.8 variants for treatment of pain |
MX2017000627A (es) * | 2014-07-16 | 2017-04-27 | Sanofi Biotechnology | Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe). |
US20160137746A1 (en) * | 2014-07-16 | 2016-05-19 | Sanofi Biotechnology | Methods for treating high cardiovascular risk patients with hypercholesterolemia |
CN107530307A (zh) * | 2015-03-13 | 2018-01-02 | 艾斯柏伦治疗公司 | 包含etc1002和依泽替米贝的固定剂量组合和制剂以及治疗心血管疾病或降低心血管疾病风险的方法 |
CA2995645A1 (fr) | 2015-08-18 | 2017-02-23 | Regeneron Pharmaceuticals, Inc. | Anticorps inhibiteurs anti-pcsk9 destines au traitement des patients atteints d'hyperlipidemie subissant une apherese de lipoproteines |
CA3008142A1 (fr) | 2015-12-11 | 2017-06-15 | The Trustees Of The University Of Pennsylvania | Therapie genique pour traiter l'hypercholesterolemie familiale |
JP7032662B2 (ja) | 2015-12-31 | 2022-03-09 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | Pcsk9抗体、その抗原結合フラグメント及び医薬用途 |
CN107531795B (zh) | 2016-01-05 | 2021-01-19 | 江苏恒瑞医药股份有限公司 | Pcsk9抗体、其抗原结合片段及其医药用途 |
US10858422B2 (en) | 2016-05-31 | 2020-12-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
CN107474140B (zh) * | 2016-06-08 | 2022-06-03 | 常州博嘉生物医药科技有限公司 | Pcsk9特异性的结合蛋白mv072及其应用 |
WO2018022511A1 (fr) | 2016-07-25 | 2018-02-01 | The Trustees Of The University Of Pennsylvania | Compositions comprenant un variant de la lécithine-cholestérol-acyl-transférase et leurs utilisations |
JP7103748B2 (ja) * | 2016-10-05 | 2022-07-20 | サッポロビール株式会社 | Pcsk9阻害剤及びコレステロール代謝改善用食品組成物 |
WO2018083248A1 (fr) | 2016-11-03 | 2018-05-11 | Kymab Limited | Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés |
WO2018152485A1 (fr) * | 2017-02-20 | 2018-08-23 | The Trustees Of The University Of Pennsylvania | Thérapie génique pour traiter l'hypercholestérolémie familiale |
MX2019012083A (es) | 2017-04-13 | 2019-11-21 | Cadila Healthcare Ltd | Nueva vacuna de peptidos contra la pcsk9. |
KR20200129127A (ko) * | 2018-03-06 | 2020-11-17 | 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 | 심혈관 위험을 감소시키기 위한 pcsk9 억제제의 용도 |
WO2020010024A1 (fr) * | 2018-07-02 | 2020-01-09 | Abcentra, Llc | Compositions et méthodes pour la réduction de la formation de la lipoprotéine a et le traitement de la sclérose valvulaire aortique et de la sténose aortique |
MX2021008533A (es) | 2019-01-18 | 2021-08-19 | Astrazeneca Ab | Inhibidores de la pcsk9 y metodos de uso de los mismos. |
Family Cites Families (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
WO1991010741A1 (fr) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation d'anticorps xenogeniques |
JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
WO1993000807A1 (fr) | 1991-07-03 | 1993-01-21 | Cryolife, Inc. | Procede de stabilisation de biomateriaux |
DE69333928T2 (de) | 1992-04-30 | 2006-08-17 | Probitas Pharma Inc., Los Angeles | Verbesserte solubilisierung und stabilisierung des faktor viii-komplexes |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
GB9410534D0 (en) | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | Improvements in or relating to growth factor inhibitors |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
JPH09154588A (ja) | 1995-10-07 | 1997-06-17 | Toagosei Co Ltd | Vegf結合性ポリペプチド |
AU2548097A (en) | 1996-03-26 | 1997-10-17 | Eli Lilly And Company | Formulations of ob protein |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
EP0852951A1 (fr) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux |
US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
US20070224663A1 (en) | 1997-03-07 | 2007-09-27 | Human Genome Sciences, Inc. | Human Secreted Proteins |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
JP4549529B2 (ja) | 1998-01-30 | 2010-09-22 | サイオス,インコーポレーテッド | ペプチドまたはタンパク質の制御放出送達 |
US7001892B1 (en) | 1999-06-11 | 2006-02-21 | Purdue Research Foundation | Pharmaceutical materials and methods for their preparation and use |
EP1514933A1 (fr) | 1999-07-08 | 2005-03-16 | Research Association for Biotechnology | Protéine sécrétoire ou protéine de membrane |
US7129338B1 (en) | 1999-07-08 | 2006-10-31 | Research Association For Biotechnology | Secretory protein or membrane protein |
US7029895B2 (en) | 1999-09-27 | 2006-04-18 | Millennium Pharmaceuticals, Inc. | 27411, a novel human PGP synthase |
AU2001241461A1 (en) | 2000-02-07 | 2001-08-14 | Millennium Pharmaceuticals, Inc. | Narc-1, novel subtilase-like homologs |
US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
ES2614260T3 (es) | 2000-05-26 | 2017-05-30 | Immunex Corporation | Uso de anticuerpos contra el receptor de interleuquina-4 y composiciones de los mismos |
WO2002020767A2 (fr) | 2000-09-08 | 2002-03-14 | Massachusetts Institute Of Technology | Composition d'analogue du g-csf et procede associe |
IL155002A0 (en) | 2000-10-12 | 2003-10-31 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
JP4317010B2 (ja) | 2001-07-25 | 2009-08-19 | ピーディーエル バイオファーマ,インコーポレイティド | IgG抗体の安定な凍結乾燥医薬製剤 |
US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
US20040191243A1 (en) | 2002-12-13 | 2004-09-30 | Bei Chen | System and method for stabilizing antibodies with histidine |
RU2332986C2 (ru) | 2003-04-04 | 2008-09-10 | Дженентек, Инк. | Высококонцентрированные композиции антител и белков |
EP1471152A1 (fr) | 2003-04-25 | 2004-10-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Mutations du gène humain PCSK9 qui sont associées à la hypercholesterolemia |
WO2004097947A2 (fr) | 2003-05-02 | 2004-11-11 | University College Cork-National University Of Ireland, Cork | Diodes electroluminescentes et leur procede de fabrication |
TWI356064B (en) | 2003-11-07 | 2012-01-11 | Immunex Corp | Antibodies that bind interleukin-4 receptor |
WO2005103081A2 (fr) | 2004-04-20 | 2005-11-03 | Genmab A/S | Anticorps monoclonaux humains diriges contre cd20 |
US20060147945A1 (en) | 2005-01-06 | 2006-07-06 | Edmonds Brian T | Novel secreted proteins and their uses |
ES2366974T3 (es) | 2006-05-05 | 2011-10-27 | Isis Pharmaceuticals, Inc. | Compuestos y procedimientos para modular la expresión de sglt2. |
WO2007134014A2 (fr) | 2006-05-05 | 2007-11-22 | Isis Pharmaceuticals, Inc. | Composés et procédés de modulation de l'expression du gcgr |
EP2029103A2 (fr) | 2006-06-16 | 2009-03-04 | Regeneron Pharmaceuticals, Inc. | Formulations antagonistes du vegf appropriées à une administration intravitréenne |
US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
RU2445318C2 (ru) | 2006-10-02 | 2012-03-20 | Ридженерон Фармасьютикалз, Инк. | Высокоаффинные антитела человека к рецептору il-4 человека |
US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
US20100040611A1 (en) | 2006-11-07 | 2010-02-18 | Sparrow Carl P | Antagonists of pcsk9 |
US20100150937A1 (en) | 2006-11-07 | 2010-06-17 | Sparrow Carl P | Antagonists of pcsk9 |
CA2667989A1 (fr) | 2006-11-07 | 2008-11-06 | Merck & Co., Inc. | Antagonistes de pcsk9 |
JP5588175B2 (ja) | 2006-11-07 | 2014-09-10 | メルク・シャープ・アンド・ドーム・コーポレーション | Pcsk9のアンタゴニスト |
EP2102340A2 (fr) | 2006-11-27 | 2009-09-23 | Isis Pharmaceuticals, Inc. | Procédés pour traiter l'hypercholestérolémie |
US8093222B2 (en) | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
CA2672049C (fr) | 2006-12-08 | 2016-05-10 | Lexicon Pharmaceuticals, Inc. | Anticorps monoclonaux diriges contre angptl3 |
CN101679527A (zh) | 2007-04-13 | 2010-03-24 | 诺瓦提斯公司 | 用于调节前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)的分子和方法 |
WO2008138536A2 (fr) | 2007-05-15 | 2008-11-20 | F. Hoffmann-La Roche Ag | Anticorps dirigé contre des récepteurs couplés à la protéine g (gpcr) |
JOP20080381B1 (ar) * | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
US20100286021A1 (en) | 2007-09-25 | 2010-11-11 | Qun-Yong Zhou | Methods of Modulating Prokineticin 2 for Treatment of Stress Response and Anxiety-Related Disorders |
SG2013014352A (en) | 2007-10-26 | 2014-09-26 | Merck Sharp & Dohme | Anti-pcsk9 and methods for treating lipid and cholesterol disorders |
AR070315A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
AR070316A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
EP4238993A3 (fr) | 2008-04-11 | 2023-11-29 | Chugai Seiyaku Kabushiki Kaisha | Molécule de liaison à l'antigène capable de se lier à deux ou plusieurs molécules d'antigène de manière répétée |
TWI516501B (zh) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9拮抗劑類 |
CN102159204B (zh) | 2008-09-19 | 2015-04-01 | 辉瑞公司 | 稳定的液体抗体制剂 |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
US8357371B2 (en) | 2008-12-15 | 2013-01-22 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to PCSK9 |
CA2754528A1 (fr) | 2009-03-06 | 2010-09-10 | Genetech, Inc. | Formulation d'anticorps |
US20120114646A1 (en) | 2009-06-18 | 2012-05-10 | Wyeth Llc | Lyophilized formulations for small modular immunopharmaceuticals |
WO2011028938A1 (fr) | 2009-09-02 | 2011-03-10 | Alnylam Pharmaceuticals, Inc. | Procédés de diminution du taux de cholestérol sérique chez un sujet à l'aide de l'inhibition de pcsk9 |
EP2480576A4 (fr) | 2009-09-25 | 2013-04-10 | Merck Sharp & Dohme | Antagonistes de pcsk9 |
EP2483682A1 (fr) | 2009-10-02 | 2012-08-08 | INSERM - Institut National de la Santé et de la Recherche Médicale | Combinaison de facteurs de risque cardiovasculaire lp(a) et d'activité de spla2 pour le diagnostic/pronostic d'une maladie/d'un événement cardiovasculaire |
WO2011053783A2 (fr) | 2009-10-30 | 2011-05-05 | Merck Sharp & Dohme Corp. | Antagonistes et variants ax213 et ax132 pcsk9 |
JP2013509191A (ja) | 2009-10-30 | 2013-03-14 | メルク・シャープ・エンド・ドーム・コーポレイション | Ax1およびax189pcsk9アンタゴニストおよびバリアント |
CA2781467C (fr) | 2009-11-20 | 2015-10-13 | Biocon Limited | Formulations d'anticorps |
AR079336A1 (es) | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
CN102844332B (zh) | 2010-03-11 | 2015-08-19 | 瑞纳神经科学公司 | 呈pH依赖性抗原结合的抗体 |
GB201005005D0 (en) | 2010-03-25 | 2010-05-12 | Angeletti P Ist Richerche Bio | New vaccine |
KR101867279B1 (ko) | 2010-10-06 | 2018-06-15 | 리제너론 파아마슈티컬스, 인크. | 항―인터류킨―4 수용체(il-4r) 항체를 함유하는 안정화된 제형 |
WO2012054438A1 (fr) | 2010-10-22 | 2012-04-26 | Schering Corporation | Anti-pcsk9 |
WO2012064792A2 (fr) | 2010-11-09 | 2012-05-18 | Altimab Therapeutics, Inc. | Complexes protéiques pour la liaison à un antigène, et leurs procédés d'utilisation |
JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
US8771696B2 (en) | 2010-11-23 | 2014-07-08 | Regeneron Pharmaceuticals, Inc. | Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor |
EA201390929A1 (ru) | 2010-12-22 | 2013-12-30 | Дженентек, Инк. | Антитела к pcsk9 и способы их применения |
PL3395836T3 (pl) | 2011-01-28 | 2021-12-13 | Sanofi Biotechnology | Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników |
KR20140006022A (ko) | 2011-02-11 | 2014-01-15 | 아이알엠 엘엘씨 | Pcsk9 길항제 |
AR088782A1 (es) | 2011-04-29 | 2014-07-10 | Sanofi Sa | Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes |
JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
US20140004122A1 (en) | 2011-05-10 | 2014-01-02 | Amgen Inc. | Methods for treating or preventing cholesterol related disorders |
JP2013023499A (ja) | 2011-07-14 | 2013-02-04 | Pfizer Inc | 抗pcsk9抗体を用いた処置 |
AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
AR087715A1 (es) | 2011-09-16 | 2014-04-09 | Lilly Co Eli | Anticuerpos anti pcsk9 y usos de los mismos |
EP2756004B1 (fr) | 2011-09-16 | 2019-12-25 | Regeneron Pharmaceuticals, Inc. | INHIBITEUR DE PROPROTÉINE CONVERTASE SUBTILISINE/KEXINE-9 (PCSK9) POUR L'UTILISATION DANS LA RÉDUCTION DU TAUX DE LIPOPROTÉINE(a) |
JP2015515279A (ja) | 2012-04-19 | 2015-05-28 | アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. | 治療に反応する患者を同定するバイオマーカーおよびそのような患者の治療 |
EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
CN104487060A (zh) | 2012-05-25 | 2015-04-01 | 克塔巴西斯制药有限公司 | 使前蛋白转化酶枯草溶菌素/kexin 9型(pcsk9)减少的方法 |
NZ704771A (en) | 2012-08-13 | 2018-02-23 | Regeneron Pharma | Anti-pcsk9 antibodies with ph-dependent binding characteristics |
EP2703009A1 (fr) | 2012-08-31 | 2014-03-05 | Sanofi | Traitements combinés impliquant des anticorps de la PCSK9 humaine |
EP2703008A1 (fr) | 2012-08-31 | 2014-03-05 | Sanofi | Anticorps humains anti-PSCK9 pour une utilisation dans des procédés de traitement des groupes de sujets particuliers |
EP2706070A1 (fr) | 2012-09-06 | 2014-03-12 | Sanofi | Traitements combinés impliquant des anticorps de la PCSK9 humaine |
TWI682780B (zh) | 2013-05-30 | 2020-01-21 | 美商再生元醫藥公司 | 醫藥組成物用於製造治療與pcsk9功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途 |
US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
TW202021614A (zh) | 2013-06-07 | 2020-06-16 | 法商賽諾菲生物技術公司 | 藉由投與pcsk9抑制劑抑制動脈粥狀硬化的方法 |
KR20230119045A (ko) | 2013-10-11 | 2023-08-14 | 사노피 바이오테크놀로지 | 고지혈증을 치료하기 위한 pcsk9 억제제의 용도 |
EP3068803B1 (fr) | 2013-11-12 | 2021-01-20 | Sanofi Biotechnology | Schémas posologiques pour l'utlisation d' inhibiteurs de la pcsk9 |
US9034332B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
EA201691320A1 (ru) | 2014-02-14 | 2016-11-30 | Ридженерон Фармасьютикалз, Инк. | Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов |
KR20220157516A (ko) | 2014-03-17 | 2022-11-29 | 사노피 바이오테크놀로지 | 심혈관 위험을 감소시키는 방법 |
US20150283236A1 (en) | 2014-03-17 | 2015-10-08 | Marie Baccara-Dinet | Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled |
US20160137746A1 (en) | 2014-07-16 | 2016-05-19 | Sanofi Biotechnology | Methods for treating high cardiovascular risk patients with hypercholesterolemia |
MX2017000627A (es) | 2014-07-16 | 2017-04-27 | Sanofi Biotechnology | Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe). |
CA2995645A1 (fr) | 2015-08-18 | 2017-02-23 | Regeneron Pharmaceuticals, Inc. | Anticorps inhibiteurs anti-pcsk9 destines au traitement des patients atteints d'hyperlipidemie subissant une apherese de lipoproteines |
US10933134B2 (en) | 2017-03-16 | 2021-03-02 | Memorial Sloan Kettering Cancer Center | Combination therapies for treatment of cancer |
-
2012
- 2012-09-12 EP EP12761864.3A patent/EP2756004B1/fr active Active
- 2012-09-12 EP EP23176223.8A patent/EP4252857A3/fr active Pending
- 2012-09-12 EA EA201490641A patent/EA028278B1/ru not_active IP Right Cessation
- 2012-09-12 CN CN202010667134.4A patent/CN111789944A/zh active Pending
- 2012-09-12 AU AU2012308797A patent/AU2012308797B2/en active Active
- 2012-09-12 US US13/611,405 patent/US10076571B2/en active Active
- 2012-09-12 SG SG2014010524A patent/SG2014010524A/en unknown
- 2012-09-12 ES ES12761864T patent/ES2773111T3/es active Active
- 2012-09-12 JP JP2014530746A patent/JP6158813B2/ja active Active
- 2012-09-12 MY MYPI2014000359A patent/MY170089A/en unknown
- 2012-09-12 EP EP19162319.8A patent/EP3536712B1/fr active Active
- 2012-09-12 WO PCT/US2012/054756 patent/WO2013039969A1/fr active Application Filing
- 2012-09-12 CN CN201280044795.5A patent/CN103930444B/zh active Active
- 2012-09-12 MX MX2014002158A patent/MX363642B/es unknown
- 2012-09-12 ES ES19162319T patent/ES2953713T3/es active Active
- 2012-09-12 BR BR112014005522A patent/BR112014005522A2/pt not_active Application Discontinuation
- 2012-09-12 CA CA2848201A patent/CA2848201C/fr active Active
- 2012-09-12 KR KR1020147009762A patent/KR101964031B1/ko active IP Right Grant
- 2012-09-14 TW TW101133592A patent/TWI601740B/zh active
- 2012-09-14 AR ARP120103399A patent/AR087881A1/es unknown
-
2014
- 2014-02-13 ZA ZA2014/01114A patent/ZA201401114B/en unknown
- 2014-02-17 IL IL231011A patent/IL231011B/en unknown
- 2014-03-06 MA MA36809A patent/MA35430B1/fr unknown
- 2014-03-13 CL CL2014000605A patent/CL2014000605A1/es unknown
- 2014-03-14 CO CO14054971A patent/CO6910163A2/es unknown
-
2017
- 2017-06-07 JP JP2017112371A patent/JP2017206520A/ja active Pending
-
2018
- 2018-08-02 US US16/053,448 patent/US11116839B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA35430B1 (fr) | Procédés de réduction du taux de lipoprotéine(a) par l'administration d'un inhibiteur de proprotéine convertase subtilisine/kexine-9 (pcsk9) | |
Hernandez-Guillamon et al. | Sequential amyloid-β degradation by the matrix metalloproteases MMP-2 and MMP-9 | |
EA202091373A1 (ru) | Стабилизированные составы, содержащие антитела анти-pcsk9 | |
Poirier et al. | The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol | |
Požgan et al. | Expression and activity profiling of selected cysteine cathepsins and matrix metalloproteinases in synovial fluids from patients with rheumatoid arthritis and osteoarthritis | |
Birkedal-Hansen et al. | Matrix metalloproteinases: a review | |
Dai et al. | Mast cell proteases and inflammation | |
Berton et al. | Involvement of fibronectin type II repeats in the efficient inhibition of gelatinases A and B by long-chain unsaturated fatty acids | |
Guarino et al. | Prolonged pharmacological inhibition of cathepsin C results in elimination of neutrophil serine proteases | |
MA34923B1 (fr) | Anticorps humains contre pcsk9 pour utilisation dans des procedes de traitement de groupes particuliers de sujets | |
Awan et al. | Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia | |
MX2015016887A (es) | Metodos para inhibir la aterosclerosis mediante la administracion de un inhibidor de pcsk9. | |
Geurts et al. | β-hematin interaction with the hemopexin domain of gelatinase B/MMP-9 provokes autocatalytic processing of the propeptide, thereby priming activation by MMP-3 | |
CO5660273A2 (es) | Formulaciones de proteina y anticuerpo de alta concentracion | |
EA201592302A1 (ru) | Способы снижения уровня остаточного холестерина и других фракций липопротеинов путем введения ингибитора пропротеиновой конвертазы субтилизин-кексинового типа 9 (pcsk9) | |
MA35800B1 (fr) | Compositions pharmaceutiques comprenant des anticorps humains contre pcsk9 | |
MA31934B1 (fr) | Formulation liquide contenant un anticorps a forte concentration | |
John et al. | Deficiency of cathepsin C ameliorates severity of acute pancreatitis by reduction of neutrophil elastase activation and cleavage of E-cadherin | |
EA200800356A1 (ru) | Лечение ингибиторами абсорбции холестерина на основе азетидинона и омега-3 жирными кислотами и их комбинированным препаратом | |
Zhan et al. | Improvement of asparagine ethylenediamines as anti-malarial Plasmodium-selective proteasome inhibitors | |
Ruettger et al. | Cathepsins B, K, and L are regulated by a defined collagen type II peptide via activation of classical protein kinase C and p38 MAP kinase in articular chondrocytes | |
Meisel et al. | Selective small-molecule inhibitors as chemical tools to define the roles of matrix metalloproteinases in disease | |
Kappert et al. | Proprotein convertase subtilisin/kexin type 3 promotes adipose tissue-driven macrophage chemotaxis and is increased in obesity | |
Ge et al. | Short-term standard alcohol consumption enhances platelet response to clopidogrel through inhibition of Nrf2/Ces1 pathway and induction of Cyp2c in mice | |
Coppola et al. | Identification of inhibitors using a cell-based assay for monitoring Golgi-resident protease activity |